Cancer biologists at EPFL, UNIGE, and the German Cancer Research Center (Heidelberg) have developed a novel immunotherapy that does not require knowledge of a tumor’s antigenic makeup. The new results may pave the way to first-in-kind clinical applications.
Unfortunately, tumors often erect barriers against the body’s immune system, allowing them to grow uncontrolled. This setback, called immunosuppression, may involve the inhibition of DCs and their ability to present tumor antigens to CD8+ T cells.
Addressing the limitations of traditional vaccines
Over the last few decades, researchers have worked to overcome tumor-induced immunosuppression by various strategies, collectively called immunotherapies, some of which are approved treatments effective in patients with certain cancers.
One approach is to generate DCs from the blood monocytes (a type of immune white blood cells) of a patient with cancer, expose them in the laboratory to defined tumor-derived material from a tumor biopsy (antigen loading step), and then reintroduce them into the patient’s body. This procedure, often referred to as a DC vaccine, is expected to significantly enhance the presentation of tumor antigens to CD8+ T cells.
However, DC vaccines have produced mixed results in clinical trials. One potential limitation is the use of monocyte-derived DCs. These cells lack certain essential properties of naturally occurring DCs, such as type I DCs (cDC1), which play a crucial role in activating CD8+ T cells.
Another potential shortcoming is its dependence on the antigen loading step, which uses predefined antigens that may not represent the full spectrum of relevant antigens present in cancer cells. Addressing the limitations of traditional DC vaccines could enhance their therapeutic efficacy.
A team of scientists led by Michele De Palma, associate professor in the School of Life Sciences and director of the Agora Cancer Research Center, has now developed engineered DCs with the capacity to differentiate into cDC1 and to stimulate anti-tumor immunity when transferred to mice with tumors, without the need for antigen loading step. The study is published in Nature Cancer.
“Our strategy does not use the monocyte-derived DCs employed in previous studies, but relies on a population of DC progenitors, called DCPs, which we can produce in vitro in the laboratory from readily available sources, such as blood and bone marrow,” De Palma explains.
Surpassing the outcomes
When engineered to express two immune-stimulatory molecules (IL-12 and FLT3L), the DCP could initiate effective anti-tumor immune responses in various cancer models, surpassing the outcomes achieved with other traditional DC formulations. “Remarkably, the engineered DCPs worked in the absence of antigen loading, which implies that they could be potentially effective against a broad range of human cancers, so irrespective of the antigens that they express.”
The ability of engineered DCPs to broadly engage multiple components of the immune system, not limited to CD8+ T cells, may explain their effectiveness. “A very promising result was the ability of the DCPs to unlock the efficacy of CAR-T cells in eradicating brain tumors in mice,” says Professor Denis Migliorini, head of neuro-oncology at UNIGE and one of the study’s authors.
CAR-T cells are another class of engineered immune cells already approved for the treatment of certain tumors, but their efficacy in brain cancer has so far been limited. “We are committed to combining DCPs with CAR-T cells in patients with incurable brain cancer,” adds Migliorini.
“Our preclinical results require further development and testing before moving to clinical application,” cautions De Palma. DCPs can be readily obtained from human blood, which should facilitate the translation of preclinical results into a potentially transformative cancer immunotherapy.
More information: Ali Ghasemi et al, Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy, Nature Cancer (2023). DOI: 10.1038/s43018-023-00668-y
News
Two Hidden Forces Help Build the Human Brain Before Birth
Scientists have uncovered two surprising forces that help guide how the human brain forms before birth. Before birth, the human brain is shaped in large part by an unusual class of stem cells known [...]
Researchers Uncover a Hidden Trigger Behind Chronic Inflammation
The findings offer new insights that could help guide the development of future therapies. A protein called human resistin may help flip on one of the immune system’s most powerful inflammatory switches. Researchers at [...]
Scientists Have Uncovered Previously Hidden Microbial Activity on Human Skin
The most abundant microbes on your skin may not be the ones doing most of the work. Human skin supports vast communities of bacteria, fungi, and viruses that can influence its protective barrier, immune [...]
Brazilian Tree Compounds Fight COVID-19 on Multiple Fronts
Scientists found compounds in a Brazilian tree that hit SARS-CoV-2 on multiple fronts, revealing a promising new lead in the search for COVID-19 treatments. Researchers have found that galloylquinic acids extracted from the leaves [...]
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
